Menu Search
Equities

Valerio Therapeutics SA

C4X:DEU

Valerio Therapeutics SA

Actions
  • Price (EUR)0.078
  • Today's Change-0.001 / -1.27%
  • Shares traded0.00
  • 1 Year change-55.17%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

  • Revenue in EUR (TTM)1.89m
  • Net income in EUR-19.66m
  • Incorporated1997
  • Employees38.00
  • Location
    Valerio Therapeutics SA49 boulevard du General Martial ValinPARIS 75015FranceFRA
  • Phone+33 145587600
  • Fax+33 145580881
  • Websitehttps://www.onxeo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.